Why the SDI (ASX:SDI) share price is falling 10% today

The dental manufacturer is gritting its teeth in a tough day of trading.

| More on:
a woman wearing a white coat like a dentist holds a pair on dentures with a grimacing look on her face and her other hand to her head

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The SDI Limited (ASX: SDI) share price is having a rocky day on the market despite the company announcing record sales in a trading update today.

Despite the sales boost, shares in the dental manufacturer dropped as low as 16% before rebounding in early afternoon trade

At the time of writing, the SDI share price is down 10.19% at 92.5 cents apiece.

Resumption in dental work a key driver of sales

Today's trading update announced a 26% increase in unaudited global sales for the six months ending 31 December 2021 to $46.2 million.

That compares to $36.8 million in sales for the same period last year and represents a record first-half performance for the company.

SDI believes the resumption of normal trading conditions last year were a key driver of the sales increase, with the exception of the New South Wales and Victorian markets due to their extended COVID-19 lockdowns.

But the company reported it has been affected by higher logistics costs in the first six months of FY22 due to the disruption in global freight activities. SDI says this has impacted gross product margins by 7%.

Despite strong sales in its Australian direct exports and in Brazil, up 65% and 66% respectively, these are lower margin regions for the company.

Overall, total gross product margins for the first half of FY22 fell by 12% to 53%, compared to 65% for the prior corresponding period.

It seems investors reacted negatively to news of an expected fall in net profit. SDI reported its net profit (after tax) for the period will be between $2.5 to $3 million, compared to $4.6 million for the same time the year prior.

The company's half-year results will be released on 17 February.

SDI is a Victorian-based manufacturer of specialised dental equipment sold in more than 100 countries.

SDI share price snapshot

Over the last 12 months, the SDI share price has increased by 26% although it has dropped almost 10% in the past month.

The company has a market capitalisation of $112 million and a price-to-earnings ratio (P/E) of 21.11.

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended SDI Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Key Canadian approval sends 10-bagger biotech's shares higher

This 10-bagger company has just released more good news, with a breakthrough in the Canadian market.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This biotech has lodged a key submission with US regulators

This company has lodged a key submission which will pave the way for sales of its heart failure software in…

Read more »